CompuGroup Medical SE & Co. KGaA (CMPUY) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
DELISTED
What happened to CompuGroup Medical SE & Co. KGaA (CMPUY) stock?
CompuGroup Medical SE & Co. KGaA (CMPUY) no longer trades on public markets. The figures below are historical and are not a current quote.
P/E 33.82 means the share price is 33.82 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $1.19B is the value of all shares combined. Beta 0.82: the stock has moved about 18% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
CompuGroup Medical SE & Co. KGaA (CMPUY). CompuGroup Medical SE & Co. KGaA is a global healthcare IT company providing software and IT solutions. Market cap: $1.19B, Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for CMPUY: CMPUY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CMPUY against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
Dated analysis: the newest financial statements on file are 24 months old (Sep 1, 2024), so the figures and score below describe that period, not today.
CMPUY: the 2 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
CompuGroup Medical SE & Co. KGaA (CMPUY) Healthcare & Pipeline Overview
CompuGroup Medical SE & Co. KGaA, a German-based healthcare IT firm, delivers software and IT solutions across four segments: Ambulatory, Pharmacy, Hospital, and Consumer Health. With a global presence and a focus on digital healthcare solutions, the company supports healthcare providers and consumers, holding a significant position in the healthcare information services sector.
What Is the Investment Thesis for CMPUY?
CompuGroup Medical SE & Co. KGaA presents a mixed investment thesis. The company's established presence in the healthcare IT sector and diverse product portfolio across ambulatory, pharmacy, hospital, and consumer health segments provide a stable revenue base. The company's P/E ratio is 33.82, and the profit margin is 1.5%. Growth catalysts include expanding digital health solutions and increasing demand for integrated healthcare systems. Potential risks include intense competition, evolving regulatory landscapes, and the relatively low profit margin. The company's beta of 0.82 suggests lower volatility compared to the market. The dividend yield is 0.22%.
Based on FMP financials and quantitative analysis
CMPUY Key Highlights
CompuGroup Medical operates in four segments: Ambulatory Information Systems (AIS), Pharmacy Information Systems (PCS), Hospital Information Systems (HIS), and Consumer & Health Management Information Systems (CHS).
- The company serves a global market, providing healthcare IT solutions to various healthcare providers and consumers.
- CompuGroup Medical's gross margin stands at 83.6%, indicating strong pricing power and efficient cost management in its software and IT solutions.
- The company's market capitalization is $1.19B, reflecting its significant presence in the healthcare IT sector.
- CompuGroup Medical has a dividend yield of 0.22%, offering a modest income stream for investors.
Who Are CMPUY's Competitors?
CMPUY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BITGF Biotage AB (publ) | $15.01 | 0.00% | $1.20B | — |
| BTTAY Biotest AG | $24.21 | -0.10% | $942M | — |
| CSWYF China Shineway Pharmaceutical Group Limited | $1.00 | 0.00% | $758M | — |
| DGWPF Drägerwerk AG & Co. KGaA | $93.00 | 0.00% | $1.74B | — |
| GDRX GoodRx Holdings, Inc. | $3.38 | +0.90% | $1.17B | 475-pillar |
| CERT Certara, Inc. | $7.47 | +0.74% | $1.16B | 375-pillar |
| TDOC Teladoc Health, Inc. | $6.11 | +0.33% | $1.11B | — |
| OMDA Omada Health | $21.50 | 0.00% | $1.28B | 435-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CMPUY's Key Strengths?
Comprehensive product portfolio across multiple healthcare segments.
- Established presence in the European healthcare IT market.
- Strong gross margin of 83.6%.
- Focus on integrated healthcare solutions.
What Are CMPUY's Weaknesses?
Relatively low profit margin of 1.5%.
- Dependence on regulatory compliance and healthcare policies.
- Limited presence in some emerging markets.
- High P/E ratio of 33.82.
What Could Drive CMPUY Stock Higher?
Increasing adoption of digital health solutions by healthcare providers and consumers.
- Expansion of integrated healthcare systems and data analytics capabilities.
- Potential strategic acquisitions to expand product offerings and market share.
- Government initiatives promoting electronic health records and telehealth services.
- Growing demand for IT security services in the healthcare sector.
What Are the Key Risks for CMPUY?
Financial-distress signal — its Altman Z-Score of 1.19 sits in the distress zone (elevated bankruptcy risk).
- Rich valuation — a P/E of 33.82 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.
- Intense competition from other healthcare IT providers.
- Evolving regulatory landscape and compliance requirements.
- Cybersecurity threats and data breaches.
- Economic downturns affecting healthcare spending.
- Currency risk associated with the ADR structure.
What Are the Growth Opportunities for CMPUY?
- Expansion of Digital Health Solutions: CompuGroup Medical has the opportunity to expand its digital health solutions, including consumer portals and mobile apps. The digital health market is experiencing rapid growth, driven by increasing consumer demand for convenient and accessible healthcare services. By enhancing its digital offerings, CompuGroup Medical can attract new customers and increase revenue.
- Integration of Healthcare Systems: The increasing demand for integrated healthcare systems presents a significant growth opportunity for CompuGroup Medical. Healthcare providers are seeking solutions that can seamlessly integrate data across different systems, improving efficiency and patient care. CompuGroup Medical can capitalize on this trend by developing and offering integrated solutions that connect ambulatory, pharmacy, hospital, and consumer health systems. This integration can lead to increased customer loyalty and higher revenue.
- Geographic Expansion: CompuGroup Medical can pursue geographic expansion to tap into new markets and increase its global presence. Emerging markets, in particular, offer significant growth potential due to increasing healthcare spending and the adoption of digital health technologies. By expanding into these markets, CompuGroup Medical can diversify its revenue streams and reduce its reliance on mature markets. This expansion requires careful market analysis and strategic partnerships to navigate local regulations and cultural differences.
- Strategic Acquisitions: CompuGroup Medical can pursue strategic acquisitions to expand its product portfolio and market share. Acquiring companies with complementary technologies or customer bases can accelerate growth and enhance the company's competitive position. Potential acquisition targets include companies specializing in telehealth, data analytics, or cybersecurity for healthcare providers. These acquisitions should be carefully evaluated to ensure they align with CompuGroup Medical's overall strategy and create synergies.
- Data Analytics and AI: CompuGroup Medical can leverage data analytics and artificial intelligence (AI) to improve its products and services. By analyzing healthcare data, the company can identify trends, predict patient outcomes, and personalize treatment plans. AI can also be used to automate tasks, improve efficiency, and reduce costs. Investing in data analytics and AI capabilities can enhance CompuGroup Medical's competitive advantage and drive innovation in the healthcare IT sector.
What Are CMPUY's Competitive Advantages?
- Established Customer Base: Long-standing relationships with a diverse customer base in the healthcare sector.
- Integrated Solutions: Comprehensive suite of integrated software solutions across ambulatory, pharmacy, hospital, and consumer health segments.
- Regulatory Expertise: Deep understanding of healthcare regulations and compliance requirements.
- Data Assets: Proprietary data assets and analytics capabilities that provide valuable insights to customers.
What Does CMPUY Do?
CompuGroup Medical SE & Co. KGaA, founded in 1987 and headquartered in Koblenz, Germany, develops and sells software and IT solutions for the healthcare sector globally. The company operates through four key segments: Ambulatory Information Systems (AIS), Pharmacy Information Systems (PCS), Hospital Information Systems (HIS), and Consumer & Health Management Information Systems (CHS). The AIS segment offers practice management software and electronic medical records for physicians and medical centers, along with supplementary internet solutions. The PCS segment provides software applications for pharmacies, focusing on administrative and billing processes, and offers decision support for medication supply chain management. The HIS segment delivers clinical and administrative solutions for hospitals, rehabilitation centers, and medical laboratories. The CHS segment provides IT security services, data-based product offerings, software interfaces, and clinical decision-making support for healthcare providers, as well as digital healthcare platforms and mobile apps for consumers. CompuGroup Medical serves a diverse clientele, including pharmaceutical companies, health insurance companies, and individual consumers. Formerly known as CompuGroup Medical SE, the company rebranded in June 2020 to CompuGroup Medical SE & Co. KGaA, reflecting its continued evolution in the healthcare IT landscape.
What Products and Services Does CMPUY Offer?
- Develops and sells software for ambulatory information systems (AIS).
- Provides software solutions for pharmacy information systems (PCS).
- Offers clinical and administrative solutions for hospital information systems (HIS).
- Creates consumer and health management information systems (CHS).
- Delivers IT security services for healthcare providers.
- Provides data-based product offers and software interfaces for information sharing.
- Offers clinical decision-making support and medication databases.
- Develops digital healthcare stock, consumer portals, and mobile apps.
How Does CMPUY Make Money?
- Software Licensing: Generates revenue through licensing its software solutions to healthcare providers and pharmacies.
- Subscription Services: Offers subscription-based services for ongoing access to its software and related support.
- IT Services: Provides IT security services and data-based product offers to healthcare organizations.
- Data Analytics: Leverages healthcare data to provide insights and analytics to improve patient outcomes and efficiency.
What Industry Does CMPUY Operate In?
CompuGroup Medical operates in the rapidly evolving healthcare IT sector. The industry is driven by increasing demand for digital health solutions, electronic health records, and integrated healthcare systems. The market is competitive, with key players including BITGF (Allscripts Healthcare Solutions), BTTAY (Cerner), CSWYF (Change Healthcare), DGWPF (Teladoc Health), and DWRKF (athenahealth). These companies compete on product offerings, technological innovation, and market reach. The healthcare IT market is expected to continue growing, fueled by government initiatives promoting electronic health records and the increasing adoption of telehealth services.
Who Are CMPUY's Key Customers?
- Registered physicians and medical care centers.
- Pharmacies and pharmaceutical companies.
- Acute care hospitals and rehabilitation centers.
- Health insurance companies.
- Consumers seeking digital health solutions.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price 5 days old
- ● Latest filing 529 days ago
- ● No analyst coverage
- ● Reported in EUR, converted to USD
MoonshotScore History
Recorded daily since 2026-08-23 · 4 snapshots
| 2026-08-23 | 48 |
| 2026-08-24 | 48 |
| 2026-08-25 | 48 |
| 2026-08-26 | 48 |
What changed?
The score has stayed at 48.
Over the same 3 days the stock moved +0.0%.
Company Profile
CompuGroup Medical SE & Co. KGaA operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Koblenz, DE. The company is led by CEO Daniel Gotthardt. CMPUY has traded publicly since 2012.
Key Financial Metrics
Return on equity for CompuGroup Medical SE & Co. KGaA stands at 0.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.2%, showing how much profit it generates from its asset base. CMPUY trades at a trailing price-to-earnings ratio of 33.82, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 7.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.12 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.4%, the inverse of the P/E and a quick read on earnings relative to price.
CMPUY Valuation & Market Position
With a $1.19B market cap, CompuGroup Medical SE & Co. KGaA sits in the small-cap segment of the market.
Quarterly Financial Performance: CompuGroup Medical SE & Co. KGaA
Revenue for CompuGroup Medical SE & Co. KGaA came in at $332.0M during Q1 FY2025, a 7.3% contraction versus the preceding quarter. The company recorded net income of $12.7M, with diluted EPS of $0.24. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, CMPUY averaged $0.15 in diluted EPS.
Financial Health
CompuGroup Medical SE & Co. KGaA's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 1.19 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project CompuGroup Medical SE & Co. KGaA revenue of about $1.04B for fiscal 2026, with EPS near $0.00. The estimate reflects 9 contributing analysts.
CMPUY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Comprehensive product portfolio across multiple healthcare segments.
- Established presence in the European healthcare IT market.
- Strong gross margin of 83.6%.
- Focus on integrated healthcare solutions.
Bear Case
- Relatively low profit margin of 1.5%.
- Dependence on regulatory compliance and healthcare policies.
- Limited presence in some emerging markets.
- High P/E ratio of 33.82.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 FY2025 | $332M | $13M | $0.24 |
| Q4 FY2024 | $358M | -$8M | -$0.15 |
| Q3 FY2024 | $329M | $10M | $0.19 |
| Q2 FY2024 | $322M | $16M | $0.31 |
Q1 FY2025 · filed 31 Mar 2025 · Financial Modeling Prep
Based on FMP financials and quantitative analysis · Converted to USD from EUR at today's rate
CMPUY Latest News
No recent news available for CMPUY.
Leadership: Daniel Gotthardt
Unknown
Therefore, a detailed career history, education, and previous roles cannot be provided. His experience prior to managing 8299 employees at CompuGroup Medical SE & Co.
Track Record: Due to the limited information available, Daniel Gotthardt's key achievements, strategic decisions, and company milestones under his leadership cannot be detailed. His specific contributions to CompuGroup Medical SE & Co.
CompuGroup Medical SE & Co. KGaA ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. CMPUY is an ADR representing shares of CompuGroup Medical SE & Co. KGaA, a German company. This allows U.S. investors to invest in the company without directly dealing with foreign exchanges.
- Home Market Ticker: Frankfurt Stock Exchange, Germany
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: CMPU
CMPUY OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that CompuGroup Medical SE & Co. KGaA has limited regulatory requirements and reporting standards compared to companies listed on major exchanges like the NYSE or NASDAQ. Companies on this tier may not be required to file regular financial reports with the SEC, leading to less transparency for investors. Investing in OTC Other stocks carries higher risks due to the limited information available.
- OTC Tier: OTC Other
- Limited Transparency: OTC stocks often have limited financial disclosure, making it difficult to assess their true value and financial health.
- Low Liquidity: Trading volumes can be thin, leading to wider bid-ask spreads and difficulty in executing large trades.
- Price Volatility: OTC stocks can be more susceptible to price manipulation and volatility due to lower trading volumes.
- Regulatory Risks: OTC companies may not be subject to the same level of regulatory scrutiny as exchange-listed companies.
- Information Asymmetry: Limited access to information can create an uneven playing field for investors.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Monitor the company's news and announcements for any updates.
- Established Business Operations: CompuGroup Medical SE & Co. KGaA has been in operation since 1987, indicating a long-standing presence in the healthcare IT sector.
- Global Presence: The company operates worldwide, serving various healthcare providers and consumers.
- Diverse Product Portfolio: CompuGroup Medical offers a comprehensive suite of software and IT solutions across multiple healthcare segments.
- ADR Listing: The existence of an ADR, even at Level I, suggests some level of compliance and oversight.
CMPUY Healthcare Stock FAQ
What happened to CompuGroup Medical SE & Co. KGaA (CMPUY) stock?
CompuGroup Medical SE & Co. KGaA (CMPUY) no longer trades on public markets. The figures below are historical and are not a current quote.
Can I still buy CMPUY shares?
No. CMPUY stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for CMPUY elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before CMPUY stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to CompuGroup Medical SE & Co. KGaA. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does CompuGroup Medical SE & Co. KGaA do?
CompuGroup Medical SE & Co. KGaA develops and distributes software and IT solutions for the healthcare industry. Its business is segmented into Ambulatory Information Systems (AIS), Pharmacy Information Systems (PCS), Hospital Information Systems (HIS), and Consumer & Health Management Information Systems (CHS).
What do analysts say about CMPUY stock?
Analyst sentiment on CMPUY stock is currently unavailable due to limited coverage. Key valuation metrics include a P/E ratio of 33.82, a gross margin of 83.6%, and a dividend yield of 0.22%.
What are the main risks for CMPUY?
The main risks for CMPUY include intense competition in the healthcare IT sector, evolving regulatory requirements, cybersecurity threats, and economic downturns affecting healthcare spending.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-16.
- OTC market data may be limited and less reliable than exchange-listed data.